Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma
NCT02814461Phase 1Completed
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axitinib in hepatocellular carcinoma (HCC), sponsored by Shin Kong Wu Ho-Su Memorial Hospital. Primary endpoint: Maximal Tolerated Dose at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02814461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814461.